Trump says Federal Reserve Board would like to see the country do badly
Reuters2026/10/07 18:53Repeats with no changes to text Oct 7 (Reuters) - US President Donald Trump, asked by a reporter on Wednesday about mortgage rates, said the Federal Reserve Board "would like to see the country do badly". The 30-year mortgage rate last week hit its highest point in almost three years. Trump called Fed chairman Kevin Warsh "great" but added the rest of the board "would like to see the country do badly, in my opinion, because I think interest rates should come down." US Treasury Secretary Scott Bessent, in the Oval Office with Trump, said inflation was high because of the energy shock". "So once we get on the other side of this Iran conflict, (the) energy market is going to be well supplied, and we will move down towards the Fed's target and mortgage rates and the 10-year will come back down," Bessent added. (Reporting by Bo Erickson, editing by David Ljunggren) ((bo.erickson@thomsonreuters.com;))
Repeats with no changes to text
Oct 7 (Reuters) - US President Donald Trump, asked by a reporter on Wednesday about mortgage rates, said the Federal Reserve Board "would like to see the country do badly".
The 30-year mortgage rate last week hit its highest point in almost three years.
Trump called Fed chairman Kevin Warsh "great" but added the rest of the board "would like to see the country do badly, in my opinion, because I think interest rates should come down."
US Treasury Secretary Scott Bessent, in the Oval Office with Trump, said inflation was high because of the energy shock".
"So once we get on the other side of this Iran conflict, (the) energy market is going to be well supplied, and we will move down towards the Fed's target and mortgage rates and the 10-year will come back down," Bessent added.
(Reporting by Bo Erickson, editing by David Ljunggren)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
